孟鲁司特钠咀嚼片联合布地奈德气雾剂吸入治疗小儿哮喘的疗效与安全性

Efficacy and Safety of Montelukast Sodium Chewable Tablets Combined with Budesonide Aerosol in Treatment of Infantile Asthma

目的:观察孟鲁司特钠咀嚼片联合布地奈德气雾剂吸入治疗小儿哮喘的临床疗效及不良反应。方法:选取2015年6月—2017年6月河南中医学院第一附属医院收治的哮喘患儿86例,采用计算机随机分组,对照组43例患儿给予布地奈德气雾剂吸入治疗,观察组43例患儿在对照组基础上加用孟鲁司特钠咀嚼片治疗,比较两组患儿的临床疗效,症状、体征消失时间及不良反应发生情况。结果:观察组患儿的总有效率为95.35%(41/43),明显高于对照组的76.74%(33/43),差异有统计学意义(P<0.05);观察组患儿的哮喘、肺部哮鸣音及咳嗽等症状、体征消失时间明显短于对照组,差异有统计学意义(P<0.05);观察组患儿的不良反应发生率为6.98%(3/43),明显低于对照组的18.60%(8/43),差异有统计学意义(P<0.05)。结论:孟鲁司特钠咀嚼片联合布地奈德气雾剂吸入治疗小儿哮喘,可有效提高临床疗效,缩短患儿症状、体征消失时间,降低不良反应发生率,安全有效。

OBJECTIVE： To observe the clinical efficacy and adverse drug reactions of Montelukast sodium chewable tablets combined with budesonide aerosol in treatment of infantile asthma. METHODS： 86 patients with infantile asthma admitted into the First Affiliated Hospital of Henan University of Traditional Chinese Medicine from Jun. 2015 to Jun. 2017 were extracted to be divided into observation group（43 cases） and control group（43 cases） via the computer-aided random grouping method. The control group was given budesonide aerosol, while the observation group additionally received Montelukast sodium chewable tablets; the clinical efficacy, disappearance time of symptoms and signs, and incidence of adverse drug reactions of two groups were observed. RESULTS： The total effective rate of observation group was 95.35% （41/43） , significantly higher than that of the control group [ 76.74% （33/43） ], with statistically significant difference （P 〈 0.05 ）. The disappearance time of asthma, lung wheezing rale and cough and sign of observation group were significantly shorten than those of control group, with statistically significant difference（P 〈0.05）. The incidence of adverse drug reactions of observation group was 6.98% （3/43） , significantly lower than that of control group [ 18.60% （8/43） ], with statistically significant diflhrence（P 〈 0.05 ）. CONCLUSIONS： Montelukast sodium chewable tablets combined with budesonide aerosol in treatment of infantile asthma can effectively improve the clinical efficacy, shorten the disappearance time of symptoms and signs, and reduce the incidence of adverse drug reactions with higher safety.